A Study of Golimumab in Participants With Active Psoriatic Arthritis
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 480
- Registration Number
- NCT02181673
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT02169973
A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT02156375
An Exploratory Genetic Study in Participants With Psoriasis
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 712
- Registration Number
- NCT02155192
Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
Phase 1
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT02154334
A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-54861911-Therapeutic DoseDrug: JNJ-54861911-Matched Placebo
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT02152332
A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 352
- Registration Number
- NCT02139943
A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Advanced Colorectal CancerColorectal Cancer With CachexiaSymptomatic Colorectal Cancer
- Interventions
- Biological: PlaceboBiological: Xilonix
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 276
- Registration Number
- NCT02138422
- Locations
- 🇵🇱
XBiotech Investigative Site, Warsaw, Poland
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 498
- Registration Number
- NCT02136134
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
Completed
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Other: No intervention
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02133092
© Copyright 2025. All Rights Reserved by MedPath